Browse EX-10 agreements

INVESTOR RIGHTS AGREEMENT

This Investor Rights Agreement, September 14, 2026 (this “Agreement”), is made by and between Dream Finders Homes, Inc., a Texas corporation (the “Company”) and the investors listed on the signature page to this Agreement (collectively, the “Investor”) (the Company and the Investor together, collectively, the “Parties”). Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Subscription Agreement (as defined below).

WHEREAS, the Company and the Investor have entered into a subscription agreement, dated September 14, 2026 (the “Subscription Agreement”), pursuant to which Investor agreed to purchase, and the Company agreed to issue to Investor, shares of the Company’s Series B Convertible Preferred Stock, par value $0.01 per share (the “Series B Convertible Preferred Stock”), that will be convertible into shares of the Company’s Class A Common Stock, par value $0.01 per share (the “Class A Common Stock”) subject to the terms and conditions therein; and

…

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of September 14, 2026, by and among Dream Finders Homes, Inc., a Texas corporation (the “Company”), and each of the parties listed on Schedule A hereto, each of which is referred to in this Agreement as a “Holder”.

RECITALS

WHEREAS, this Agreement is made pursuant to that certain Subscription Agreement, dated as of September 14, 2026, by and between the Company and each Holder (the “Subscription Agreement”);

WHEREAS, the Holders and the Company hereby agree that this Agreement shall govern the rights of the Holders to cause the Company to register Registrable Securities (as defined below) held or issuable to the Holders as set forth in this Agreement;

NOW, THEREFORE, the parties hereby agree as follows:

1.Definitions. For purposes of this Agreement:

…

VOTING AGREEMENT

THIS VOTING AGREEMENT, dated as of September 14, 2026, is entered into by and between (i) Dream Finders Homes, Inc., a Texas corporation (the “Company”), and (ii) Patrick O. Zalupski (the “Stockholder”). Capitalized terms used herein without definition shall have the meanings set forth in Section 1.1.

W I T N E S S E T H:

WHEREAS, the Company proposes to issue and sell to certain accredited investors pursuant to a subscription agreement shares of a new series of its preferred stock to be designated as “Series B Convertible Preferred Stock” (the “Convertible Preferred Stock”) that will be convertible into shares of Class A Common Stock, par value $0.01 per share, of the Company (the “Class A Common Stock”) (such issuance and sale of Convertible Preferred Stock, the “Preferred Issuance”);

…

REGISTRATION RIGHTS AGREEMENT

This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 14, 2026, between GT Biopharma, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).

NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser hereby agrees as follows:

1. Definitions.

Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

“Advice” shall have the meaning set forth in Section 6(c).

…

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of September 14, 2026, between GT Biopharma, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

…

LOCK-UP AGREEMENT

September 14, 2026

GT Biopharma, Inc.

	Re:	Securities Purchase Agreement, dated as of September 14, 2026 (the “Purchase Agreement”), between GT Biopharma, Inc. (the “Company”) and the purchasers signatory thereto (each, a “Purchaser” and, collectively, the “Purchasers”)

Ladies and Gentlemen:

…

TO:	The Purchasers of GT Biopharma, Inc., Series M 10% Convertible Preferred Stock and Warrants

To Whom It May Concern:

This letter will confirm my agreement to vote all shares of GT Biopharma, Inc. (“GTBP”) voting stock over which I have voting control in favor of any resolution presented to the shareholders of GTBP to approve the issuance, in the aggregate, of more than 19.99% of the number of shares of common stock of GTBP outstanding on the date of closing pursuant to that certain Securities Purchase Agreement, dated September 14, 2026, among GTBP and the purchasers signatory thereto (the “Purchase Agreement”) and the other agreements entered into in connection therewith or as otherwise may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity). This agreement is given in consideration of, and as a condition to ent

…

EMPLOYMENT** AGREEMENT **

This Employment Agreement (the “Agreement”) is made effective as of September 13, 2026 (the “Effective Date”), by and between Catalyst Bank (the “Bank”) and Amanda Quebedeaux (“Executive”).

WHEREAS, the Bank wishes to assure itself of the services of Executive for the period provided in this Agreement; and

WHEREAS, in order to continue Executive’s employment with the Bank and to provide incentive for Executive to achieve the financial and performance objectives of the Bank, the parties desire to enter into this Agreement; and

WHEREAS, the Bank desires to set forth the rights and responsibilities of Executive and the compensation payable to Executive, as modified from time to time.

NOW, THEREFORE, in consideration of the mutual covenants herein contained, and upon the other terms and conditions hereinafter provided, the parties hereby agree as follows:

1.POSITION AND RESPONSIBILITIES.

…

EMPLOYMENT AGREEMENT

This Employment Agreement (the “Agreement”) is made effective as of September 13, 2026 (the “Effective Date”), by and between Catalyst Bank (the “Bank”) and Jacques Bourque (“Executive”).

WHEREAS, the Bank wishes to assure itself of the services of Executive for the period provided in this Agreement; and

WHEREAS, in order to continue Executive’s employment with the Bank and to provide incentive for Executive to achieve the financial and performance objectives of the Bank, the parties desire to enter into this Agreement; and

WHEREAS, the Bank desires to set forth the rights and responsibilities of Executive and the compensation payable to Executive, as modified from time to time.

NOW, THEREFORE, in consideration of the mutual covenants herein contained, and upon the other terms and conditions hereinafter provided, the parties hereby agree as follows:

1.POSITION AND RESPONSIBILITIES.

…

AETHLON MEDICAL, INC.

AMENDMENT NO. 2 TO
EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 2 to Executive Employment Agreement (this “Amendment”) is made and entered into as of September 11, 2026 (the “Amendment Effective Date”), by and between James B. Frakes (“Employee”) and Aethlon Medical, Inc., a Nevada corporation (the “Company”). The Company and Employee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

…

AETHLON MEDICAL, INC.

AMENDMENT NO. 1 TO
EXECUTIVE EMPLOYMENT AGREEMENT

This Amendment No. 1 to Executive Employment Agreement (this “Amendment”) is made and entered into as of September 11, 2026 (the “Amendment Effective Date”), by and between Steven P. LaRosa, MD (“Employee”) and Aethlon Medical, Inc. (the “Company”). The Company and Employee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

	A.	The Company and Employee are parties to that certain Executive Employment Agreement dated as of January 4, 2021 (the “Agreement”).

…

---

Exhibit 10.1

September 13, 2026

Judith F. Marks

At the address last on file with the Company

RE:  Transition and Retirement

Dear Judy:

On behalf of Otis Worldwide Corporation (together with all of its subsidiaries, divisions and affiliates are hereafter referred to collectively as the “Company”), I want to thank you for your many years of service to the Company, during which you have demonstrated exceptional leadership and made significant contributions to the Company as Chair, Chief Executive Officer and President.  We appreciate your willingness to provide continued support and expertise to the Company as we navigate this leadership transition.

…